Author:
Albrecht Camille,Kuznetsov Andrey S.,Appert-Collin Aline,Dhaideh Zineb,Callewaert Maïté,Bershatsky Yaroslav V.,Urban Anatoly S.,Bocharov Eduard V.,Bagnard Dominique,Baud Stéphanie,Blaise Sébastien,Romier-Crouzet Béatrice,Efremov Roman G.,Dauchez Manuel,Duca Laurent,Gueroult Marc,Maurice Pascal,Bennasroune Amar
Abstract
Sialidases, or neuraminidases, are involved in several human disorders such as neurodegenerative, infectious and cardiovascular diseases, and cancers. Accumulative data have shown that inhibition of neuraminidases, such as NEU1 sialidase, may be a promising pharmacological target, and selective inhibitors of NEU1 are therefore needed to better understand the biological functions of this sialidase. In the present study, we designed interfering peptides (IntPep) that target a transmembrane dimerization interface previously identified in human NEU1 that controls its membrane dimerization and sialidase activity. Two complementary strategies were used to deliver the IntPep into cells, either flanked to a TAT sequence or non-tagged for solubilization in detergent micelles. Combined with molecular dynamics simulations and heteronuclear nuclear magnetic resonance (NMR) studies in membrane-mimicking environments, our results show that these IntPep are able to interact with the dimerization interface of human NEU1, to disrupt membrane NEU1 dimerization and to strongly decrease its sialidase activity at the plasma membrane. In conclusion, we report here new selective inhibitors of human NEU1 of strong interest to elucidate the biological functions of this sialidase.
Funder
Ligue Contre le Cancer
Agence Nationale de la Recherche
Subject
Cell Biology,Developmental Biology
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献